-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HJhH2ydgKpMof/xU9Wbzmr/LEBj7D+vpAU3lHb4V44LyN4ukRJ8MECwayrNIzTER ygt2Tg4I0+pPcWOUP60+EQ== 0000950133-97-000370.txt : 19970222 0000950133-97-000370.hdr.sgml : 19970222 ACCESSION NUMBER: 0000950133-97-000370 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19970211 ITEM INFORMATION: Change in fiscal year FILED AS OF DATE: 19970212 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC CENTRAL INDEX KEY: 0000737207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112658569 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13789 FILM NUMBER: 97527037 BUSINESS ADDRESS: STREET 1: 129 OSER AVE CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: 5162730101 MAIL ADDRESS: STREET 1: 45 DAVIDS DRIVE CITY: HAUPPAUGE STATE: NY ZIP: 11788 8-K 1 NASTECH PHARMACEUTICAL COMPANY INC. 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FEBRUARY 11, 1997 Date of Report (Date of earliest event reported) NASTECH PHARMACEUTICAL COMPANY INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 0-13789 11-2658569 (State or other jurisdiction of (Commission File No.) (I.R.S. Employer Identification No.) incorporation or organization)
45 DAVIDS DRIVE, HAUPPAUGE, NEW YORK, 11788 (Address of Principal Executive Offices) (516) 273-0101 (Registrant's telephone number, including area code) ITEM 8. CHANGES IN FISCAL YEAR. On February 11, 1997, the Registrant's Board of Directors voted to change the Registrant's fiscal year from June 30 to December 31, effective December 31, 1996. The report covering the transition period will be filed on Form 10-K for the twelve month period ended December 31, 1996. The Form 10-K will be filed with the Commission on or before May 11, 1997. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NASTECH PHARMACEUTICAL COMPANY INC. (Registrant) By: /s/ Dr. Vincent D. Romeo ---------------------------------------- DR. VINCENT D. ROMEO, President and Chief Executive Officer DATED: February 11, 1997 -----END PRIVACY-ENHANCED MESSAGE-----